

AWARDEES

- **2025 ASCO President-elect**
Eric Small, MD, FASCO
- **Newly Appointed ASCO Committee Leaders**
 - Amy Jo Chien, MD, Chair-Elect, Annual Meeting Scientific Program Committee
 - Sam Brondfield, MD, MA Chair-Elect, Education Council
 - Niharika Dixit, MD Chair-Elect, Health Policy Committee
- **Featured Voices #ASCO24**
 - Ana I. Velázquez Mañana, MD MS
- **Young Investigator Awards**
 - William S. Chen, MD
 - Lindsey M. Draper, MD
 - Kelsey Natsuhara, MD
 - Michael P. Randall, MD
 - Noah Younger, MD, PhD
- **Annual Meeting Merit Awards**
 - Kirkpatrick Fergus, MD
 - Mulki Mehari,
 - Ali Sabbagh, MD
- **Annual Meeting Research Awards**
 - Kevin Reyes, BS
- **Medical Student Rotation**
 - Kevin Reyes, BS
- **Oncology Summer Internships**
 - Asmaa Mahoui
 - Alvine Nguounga
 - Maria Gonzalez
 - Pearl Omo-sowho
 - Diego Martinez Mendiola
 - Austine Peng
 - Mallory Shingle
 - Isaac Avila-Vargas



PRESENTATIONS AND POSTER SESSIONS BY DATE

FRIDAY, May 31

1:00 PM CT | E253D

ASCO Artificial Intelligence Community of Practice Meeting

[Brief Panel: Potential priorities of AI CoP and introduction to breakouts](#)
Julian Hong, MD, MS

6:30 PM CT | Hilton, Blvd Room Ancillary Educational Event

[Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies](#)
Moderator Hope S. Rugo, MD, FASCO

SATURDAY, June 1

PRESENTATIONS

8:00 AM CT | S100a

**Melanoma/Skin Cancers
Case Based Panel**

The Promise of Neoadjuvant Immunotherapy Across Solid Tumors

MODERATOR: Katy K. Tsai, MD

Navigating Melanoma Management From Early Stages to Post-Adjuvant Therapy

This case-based panel will address multidisciplinary care for patients with stage II melanoma.

8:00 AM CT | E451

**Gynecological Cancer
Rapid Oral Abstract Session**

Katherine Cynthia Fuh, MD, PhD

Abstract: 5515

[AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept \(AVB-S6-500\) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.](#)

8:30 AM CT

**Women in Oncology
Panel Talk: *Leading From Within: Cultivating***

Authenticity

Moderator Sonya Reid, MD, MPH | Vanderbilt-Ingram Cancer Center

Panelists

- Cathy Eng, MD, FACP, FASCO | Vanderbilt-Ingram Cancer Center
- Reshma Jagsi, MD, DPhil | Emory University School of Medicine
- **Katherine Van Loon, MD, MPH | UCSF**

3:00 PM | E450a

**Central Nervous System Tumors
Clinical Science Symposium**

Benjamin Joshua Lerman, MD, MS

Abstract: 2099

[Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence.](#)

3:00 PM | S406

**Lung Cancer
Education Session**

Matthew A. Gubens, MD, MS, FASCO

[Metastatic Non-Small Cell Lung Cancer With Oncogene Addiction/Driver Mutation \(not EGFR\)](#)

SATURDAY, June 1

POSTERS

8:00 AM CT
Hall A | On Demand

Developmental Therapeutics - Immunotherapy

Jordan Guillot, PhD, PharmD

Abstract: 2555 | Poster Bd #: 34

Constructing adverse event timelines for patients receiving CAR-T therapy using large language models.

Adil Daud, MD

Abstract: 2575 | Poster Bd #: 54

Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Hope S. Rugo, MD, FASCO

Abstract: 3029 | Poster Bd #: 174

Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types.

Central Nervous System Tumors

Mulki Mehari, B.A.

Abstract: 2048 | Poster Bd #: 347

Can targeting TSP-1 with gabapentin enhance survival in glioblastoma? A 20-year retrospective cohort study.

Care Delivery/Models of Care

Arda Demirci, BA

Abstract: 1561 | Poster Bd #: 432

Large language models to evaluate racial discrepancies in performance status assignment.

Constance Wu, MD, MPhil

Abstract: 1576 | Poster Bd #: 447

Lessons learned from a genetic counseling randomized clinical trial: Implications for recruiting individuals identifying as Asians in research.

Kevin R Reyes, BS

Abstract: 1605 | Poster Bd #: 476

Unveiling inequities in representation: Racial disparities in supportive care breast cancer clinical trial enrollment.

Mulki Mehari, B.A.

Abstract: 1614 | Poster Bd #: 485

Predicting therapeutic clinical trial enrollment for underrepresented patients in neuro-oncology using supervised machine learning.

Ana I. Velazquez Manana, MD, MSc, MS

Abstract: 1619 | Poster Bd #: 490

Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators.

1:30 PM CT
Hall A | On Demand

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Robin Kate Kelley, MD

Abstract: 4022 | Poster Bd #: 2

T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC).

SUNDAY, June 2

PRESENTATIONS

9:45 AM | E450a

Education Session

ASCO/AACR Joint Session: Drugging the “Undruggable”

Target: Successes, Challenges, and the Road Ahead

Kevan M. Shokat, PhD

The Story of KRAS-Directed Therapy From Bench to Bedside: A Roadmap for Success?

11:30 AM CT | S406

Rapid Oral Abstract Session

Dev Therapeutics—Immuno

Zoe Quandt, MD, MS

Abstract: 2516

HLA associations with immunotherapy related endocrine toxicity.

POSTERS

8:00 AM CT
Hall A | On Demand

Breast Cancer—Metastatic

Hope S. Rugo, MD, FASCO

Abstract: 1069 | Poster Bd #: 47

Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.

Laura Ann Huppert, MD

Abstract: 1083 | Poster Bd #: 61

Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies.

Samantha Catherine Fisch, MD

Abstract: 1108 | Poster Bd #: 86

A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.

Genitourinary Cancer—Prostate, Testicular, and Penile

Ali Sabbagh, MD

Abstract: 5065 | Poster Bd #: 471

Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer.

Nonna Shakhnazaryan, BS

Abstract: 5066 | Poster Bd #: 472

A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

Daniel H Kwon, MD | UCSF

Abstract: 5105 | Poster Bd #: 511

Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.

MONDAY, June 3

PRESENTATIONS

8:00 AM CT | S100bc **Rapid Oral Abstract Session**
Central Nervous Sys Tumors

John Frederick de Groot, MD **Abstract: 2005**
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.

1:15 PM CT | B1 **Rapid Oral Abstract Session**
Genitourinary Cancer

Rahul Raj Aggarwal, MD **Abstract: 5012**
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).

3:00 PM | S100a **Education Session**
State of the Art in Gynecologic Cancer: New Drugs and
Companion Diagnostics

Katherine Fuh, MD, PhD
Which Antibody-Drug Conjugates Should We Choose and How Should We Manage Them?

4:30 PM | S100a **Clinical Science Symposium**
Symptom Science/Palliative Care

Steven Pantilat, FAAHPM, FACP, MHM
Hope Beyond a Cure

POSTERS

9:00 AM CT
Hall A | On Demand

Care Delivery and Quality Care

Amrita B Basu, PhD | UCSF **Abstract: 11113 Poster: 308**
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I SPY2.

POSTERS

1:30 PM CT
Hall A | On Demand

Lung Cancer

Turja Chakrabarti, MD, MS

Abstract: 8572

A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer.

Medical Education and Professional Development

Sam Brondfield, MD, MA

Abstract: 9017

Observing attending physician teaching behaviors during inpatient hematology/oncology consultation.

Prevention, Risk Reduction, and Genetics

Nishwant Swami, MD, MPH, Hospital of the University of Pennsylvania

(Scarlett Gomez and Iona Cheng, senior authors). Abstract: 10561

Associations of prior lung diseases on risk of lung cancer in populations with no smoking history: A systematic review and meta-analysis.

Breast Cancer—Local/Regional/Adjuvant

Roberto Antonio Leon-Ferre, MD | Mayo Clinic

(Laura Esserman, senior author)

Abstract: 594

Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.

Alexandra Thomas, MD, FACP | Duke Cancer Institute

(Laura Esserman, senior author)

Abstract: 582

Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.